Pfizer drug shows mixed results in psoriasis trials

(Reuters) - A high dose of Pfizer Inc's drug, tofacitinib, proved as effective as the widely used treatment, Enbrel, in treating adults with moderate-to-severe psoriasis in a late-stage study , while a lower dose of tofacitinib was less effective than Enbrel, the drugmaker said on Wednesday.

Source: Reuters: Health - October 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news